Skip to main navigation Skip to search Skip to main content

A multicenter phase II study of tgDCC-E1A for the intratumoral treatment of patients with recurrent head and neck squamous cell carcinoma

  • Doug Villaret
  • , Bonnie Glisson
  • , Daniel Kenady
  • , Ehab Hanna
  • , Mary Carey
  • , Lyon Gleich
  • , George H. Yoo
  • , Neal Futran
  • , Mien Chie Hung
  • , Pervin Anklesaria
  • , Alison E. Heald

Research output: Contribution to journal › Article › peer-review

Abstract

Background. The anti-cancer gene, E1A, can be complexed to a lipid carrier, DC-Cholesterol: DOPE, to form tgDCC-E1A, which can be injected directly into tumors. Methods. Twenty-four patients with recurrent, unresectable, head and neck cancer were treated with intratumoral injections of tgDCC-E1A over 8 weeks. Tumor response was assessed using CT scans. Time to progression and overall survival were calculated. Results. Intratumoral tgDCC-E1A was well tolerated in all patients. No significant toxicities related to tgDCC-E1A were reported. One patient (4.2%) had a complete response, two patients (8.3%) had minor response, and seven patients (29.2%) had stable disease by two-dimensional cross-products on blinded CT scans. The median time to progression was 8.6 weeks (range, 3.3-43.7 weeks), and median survival was 4.6 months (range, 1.3-15.6 months). Conclusions. Intratumoral injections of tgDCC-E1A were safe and well tolerated. Modest tumor response was observed. Further development of tgDCC-E1A is warranted in combination with other treatment modalities.

Original languageEnglish (US)
Pages (from-to)661-669
Number of pages9
JournalHead and Neck
Volume24
Issue number7
DOIs
StatePublished - 2002

Keywords

  • Adenovirus E1A gene
  • E1A-Lipid Complex
  • Gene transfer
  • Head and neck cancer
  • Liposome

ASJC Scopus subject areas

  • Otorhinolaryngology

Fingerprint

Dive into the research topics of 'A multicenter phase II study of tgDCC-E1A for the intratumoral treatment of patients with recurrent head and neck squamous cell carcinoma'. Together they form a unique fingerprint.

Cite this